

## Accepted Manuscript

Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis

Remington L. Nevin



PII: S8756-3282(18)30257-6  
DOI: doi:[10.1016/j.bone.2018.06.025](https://doi.org/10.1016/j.bone.2018.06.025)  
Reference: BON 11691  
To appear in: *Bone*  
Received date: 14 June 2018  
Accepted date: 30 June 2018

Please cite this article as: Remington L. Nevin , Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis. *Bone* (2018), doi:[10.1016/j.bone.2018.06.025](https://doi.org/10.1016/j.bone.2018.06.025)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Considerations in the Repurposing of Mefloquine for Prevention and Treatment of Osteoporosis**

Remington L. Nevin, MD, MPH, DrPH

Executive Director

The Quinism Foundation

P.O. Box 145

White River Junction, VT 05001

rnevin@quinism.org

**Word Count:** 384

**References:** 11

**Conflict of Interest Statement:** The author serves as consultant and expert witness in legal cases involving claims of adverse effects from antimalarial drugs.

Download English Version:

<https://daneshyari.com/en/article/8624821>

Download Persian Version:

<https://daneshyari.com/article/8624821>

[Daneshyari.com](https://daneshyari.com)